Journal article
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, C Scott, W Meier, R Shapira-Frommer, T Safra, D Matei, A Fielding, B Bennett, D Parry, S Spencer, H Mann, U Matulonis
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2016
DOI: 10.1038/bjc.2016.348
Abstract
Background:Maintenance monotherapy with the poly(ADP-ribose) polymerase inhibitor olaparib significantly prolongs progression-free survival over placebo in patients with platinum-sensitive relapsed serous ovarian cancer, with greatest benefit seen in patients with a BRCA1/2 mutation (BRCAm). Preservation of health-related quality of life (HRQoL) is important during maintenance therapy; we evaluated the effect of olaparib on HRQoL in this Phase II trial (NCT00753545, Study 19).Methods:Patients received olaparib 400 mg b.i.d. (capsules) or placebo until progression. Patient-reported HRQoL and disease-related symptoms were evaluated using the FACT-Ovarian (FACT-O) questionnaire (completed at ba..
View full abstractGrants
Funding Acknowledgements
Medical writing assistance during the development of this manuscript was provided by Rachel Patel from Mudskipper Business Ltd, funded by AstraZeneca. This work was supported by funding from AstraZeneca.